Concepedia

OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).

C. Aghajanian, N. J. Finkler, T. Rutherford, D. A. Smith, J. Yi, Hardik Vijay Parmar, L. R. Nycum, M. A. Sovak

Journal of Clinical Oncology · 2011 · 21 citations · 0 references

Concepts

MedicineGynecologyOncologyChemotherapyGynecologic OncologyOncology PharmacotherapyFallopian Tube CancerGynecologic Cancer PharmacotherapyMalignant NeoplasmsOvarian CancerOvarian Cancer PharmacotherapyOvarian Cancer ChemotherapyOvarian Cancer Clinical TrialsOvarian Cancer TreatmentPlatinum SensitivityRecurrent Ovarian CancerRecurrent Platinum-sensitive Ovarian Cancer

Abstract

LBA5007 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.